Paper Details

  1. Home
  2. Paper Details

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.

Author: BörnsenLars, DyrbyTim B, GardeEllen, LyksborgMark, RatzerRikke, Romme ChristensenJeppe, SellebjergFinn, SiebnerHartwig R, SorensenPer S

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Natalizumab treatment of progressive MS reduces intrathecal inflammation and tissue damage, supporting a beneficial effect of natalizumab treatment in progressive MS.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Natalizumab inhibits the migration of systemic immune cells to the CNS and may be beneficial in progressive multiple sclerosis (MS). The objective of the study was to examine the effects of natalizumab in progressive MS. METHODS: In an open-label phase 2A study, 24 patients with progress...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/WNL.0000000000000361

データ提供：米国国立医学図書館（NLM）

Natalizumab for Progressive MS: A Beacon of Hope in the Desert of Neurological Disease

The search for effective treatments for progressive multiple sclerosis (MS) is a daunting journey through the desert of neurological disease. This study investigates the potential of natalizumab, an immune-modulating medication, for treating progressive MS. Researchers conducted an open-label phase 2A study to assess the effects of natalizumab in patients with progressive MS. Their findings indicate that natalizumab treatment reduces intrathecal inflammation and tissue damage, suggesting a beneficial effect in progressive MS. This discovery is like finding a wellspring of hope in the desert of MS, offering a potential new strategy for managing this debilitating condition.

A Wellspring of Hope: Natalizumab's Potential

This study suggests that natalizumab may offer a valuable tool in the fight against progressive MS. It's like finding a freshwater spring in the desert, offering relief from the harsh conditions of the disease.

Navigating the Desert of Neurological Disease: Practical Implications for Everyday Life

This research offers a glimmer of hope for individuals struggling with progressive MS. While further research is needed to fully understand its potential, this study demonstrates the importance of ongoing research in finding new and effective treatments for neurological disorders.

Dr.Camel's Conclusion

This study provides a hopeful oasis in the desert of progressive MS. The potential of natalizumab to reduce inflammation and tissue damage is encouraging. However, we must continue to explore this desert, seeking new and innovative treatments to improve the lives of individuals with this debilitating disease.

Date :
  1. Date Completed 2014-06-23
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

24682973

DOI: Digital Object Identifier

10.1212/WNL.0000000000000361

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.